Results 51 to 60 of about 67,544 (271)

A novel role for CD36 in VLDL-enhanced platelet activation [PDF]

open access: yes, 2003
Type 2 diabetes is characterized by increased plasma triglyceride levels and a fourfold increase in ischemic heart disease, but the mechanism is unclear. CD36 is a receptor/transporter that binds fatty acids of lipoproteins.
Aitman, T.J.   +9 more
core   +1 more source

Biomimetic Core–Shell Liposome Nanoparticles Deplete Lipoproteins and Enhance the Purity of Extracellular Vesicles from Human Blood

open access: yesAdvanced Functional Materials, EarlyView.
Lipoprotein‐mimicking nanoparticles (SL‐NPs), comprising Fe3O4@SiO2 cores coated with liposomal bilayers, selectively capture lipoproteins through protein corona formation. The resulting SL‐NP‐lipoprotein complexes can be removed by low‐speed centrifugation, thereby enhancing the purity of small extracellular vesicles (sEVs) isolated from human serum ...
Man‐Di Wang   +7 more
wiley   +1 more source

Acetaldehyde adducts and autoantibodies against VLDL and LDL in alcoholics

open access: yesJournal of Lipid Research, 1993
Alcohol consumption markedly increases the hepatic output of very low density lipoprotein (VLDL), whereas it decreases the resulting low density lipoprotein (LDL) levels and apolipoprotein B.
H Wehr, M Rodo, CS Lieber, E Baraona
doaj   +1 more source

VLDL-TG secretion in Lipg-/- mice.

open access: yes, 2021
A. Plasma triglycerides in mice at the indicated timepoints following intraperitoneal injection of poloxamer P407, a competitive inhibitor of LPL activity. Plasma TGs were measured by colorimetric biochemical assays. B. VLDL-TG secretion rates calculated
Papasani V. Subbaiah (232673)   +12 more
core   +1 more source

How is Nanoarchitectonics Shaping Extracellular Vesicle Research?

open access: yesAdvanced Healthcare Materials, EarlyView.
The convergence of nanoarchitectonics and extracellular vesicle biology is reshaping next‐generation nanomedicine by enabling rationally designed nanostructures for enhanced EVs detection, engineering, and therapy. ABSTRACT Extracellular vesicles (EVs) have gained recognition as crucial mediators of cell‐to‐cell communication, holding immense potential
Madushani Dahanayake   +5 more
wiley   +1 more source

Distribution of apolipoproteins A-I and B among intestinal lipoproteins.

open access: yesJournal of Lipid Research, 1985
Chylomicrons and very low density lipoproteins (VLDL) are produced by the intestine and these nascent particles are thought to be similar to their counterparts in intestinal lymph.
D H Alpers   +4 more
doaj   +1 more source

Harnessing Large‐Scale Multi‐Omics Data for Risk Prediction and Deep Phenotyping of Valvular Heart Diseases in the General Population

open access: yesAdvanced Science, EarlyView.
Large‐scale UK Biobank analyses identify clinical and proteomic signatures for early prediction of valvular heart disease and its subtypes. Proteins add predictive value for VHD, AVS, and MVR, with outcome‐specific compact panels showing translational potential. Multi‐layer evidence highlights matrix remodeling, protease regulation, immune inflammation,
Zhihao Jiang   +10 more
wiley   +1 more source

Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway.

open access: yesJournal of Lipid Research, 1996
Very low density lipoproteins (VLDL) are produced in the liver and contain apolipoprotein (apo) B-100 and endogenous lipids. By contrast, ingestion of fat leads to formation of chylomicrons containing apoB-48 secreted from the intestine. In this study, a
J Bjorkegren   +8 more
doaj   +1 more source

Application of enzymatic fluorometric assays to quantify phosphatidylcholine, phosphatidylethanolamine and sphingomyelin in human plasma lipoproteins. [PDF]

open access: yes, 2021
pdfPhosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM) are important surface components of plasma lipoproteins, including very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
MORITA, Shin-ya   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy